Fig. 1

Relationship between proportion of diabetic patients at inclusion (%) and primary outcome rates (%/year; left panels) or total coronary heart disease (CHD) events (%/year; right panels) in comparator arms (upper panels) and in treatment arms (lower panels) of 33 landmark trials that included a substantial minority of diabetics (ranging from 2 % to 44 %), representing a total of 259,151 patients. The graphs are based on data from the following trials: 4S; AFCAPS/TexCAPS; AIM-HIGH; ALERT; ALLHAT-LLT; Alpha-Omega; ASCOT-LLA; AURORA; BIP; CARE; CDP; dal-OUTCOMES; GISSI-Prevenzione; GREACE; HATS; HHS; HPS-MRC/BHF; HPS2-THRIVE; IDEAL; ILLUMINATE; JELIS; LEADER; LIPID; LIPS; MEGA; PERFORM; Post-CABG; PROSPER; SHARP; STABILITY; TNT; VA Cooperative Study; and VA-HIT. The open diamonds represent primary outcome rates and CHD events from the following diabetes substudies: 4S; ASCOT-LLA; AURORA; CARE; GREACE; HHS; HPS-MRC/BHF; TNT; and VA-HIT. See Table 1 for acronyms definition and trials’ references, and Table 2 and Table 4 for primary outcomes classification and description